


**ONCOGENES AND FLOW CYTOMETRIC STUDIES
IN
BREAST CANCER**

Thesis

**Submitted For Partial Fulfilment Of
Ph.D Degree In Biochemistry**

By

**Azza Hassan Ahmed Abou Ghalia
M.Sc. Biochemistry**



616.99449

A . H

Supervisors

50/01

**Prof. Dr. Ali Khalifa
Prof. Of Biochemistry
Faculty Of Medicine
Ain Shams University**

**Prof. Dr. Robert C. Bast Jr.
Director, Duke Comprehensive
Cancer Center**

**Dr. Mostafa M. El Rasad
Prof. Of Biochemistry
Faculty Of Medicine
Ain Shams University**

**Dr. Ahmed Salah Kamel
Ass. prof. Of Pathology
Faculty Of Medicine
Ain Shams University**


**Dr. Sanaa Eissa Mohamed
Lecturer of Biochemistry
Faculty of Medicine
Ain Shams University**




1994

Approval Sheet


Prof. Dr. Gameel A. Tawdros



Prof. Dr. Fawzeya K. Khalil



Prof. Dr. Ali Khalifa Ali



Prof. Dr. Moustafa Al-Rassad





Acknowledgement

*"First of all thanks **GOD** who supplies me power to overcome problems".*

*I would like to express my gratitude and esteem to **Prof. Dr. Ali Khalifa Ali**; Professor of Biochemistry and Head of Oncology Diagnostic Unit, faculty of medicine, Ain Shams University and **Prof Dr, Robert C. Bast, Jr.**; Head, Division of Medicine, M.D Anderson cancer center not only for guiding the choice of the subject and laid out the work plan but also they continually gave their productive advice and sincere encouragement. Thanks to their effort, this thesis came to a conclusion.*

*I am honored to have **Dr Jeffery R. Marks**, Assistant Professor. Department of Surgery Duke University Medical Center, and I am indebted to him for his valuable advice and continuous guidance without which this thesis would have not been delivered in this form.*



DUKE COMPREHENSIVE CANCER CENTER

f the Director

March 24, 1994

RE: AZZA ABOU-GHALIA

To Whom It May Concern:

Dr. Azza Abou-Ghalia has performed post-doctoral studies in my laboratory between September 1992 and March of 1994. During this time she developed and compared different methods for detecting breast cancer micrometastases in bone marrow. A two-color immunofluorescent technique was developed that permitted detection of breast cancer cells by flow cytometry with greater precision than could be achieved with single color immunofluorescence. She had explored the possibility of using ligase chain reactions to detect cells with mutated p53 in bone marrow. She also had undertaken studies to compare mutations of p53 in primary breast cancers with mutations in p53 of cells sorted from marrow using monoclonal antibodies. In these studies she demonstrated the ability to learn new techniques and to develop her own experiments. Dr. Abou-Ghalia has shown great persistence in carrying out her studies and in writing a thesis. She clearly grew in her knowledge of science during the year and a half that she had spent with our group. I can recommend her to you with great enthusiasm as a physician/scientist with a sincere interest in translational research.

Sincerely,

Robert C. Bast Jr., M.D.
R. Wayne Rundles Professor of Medicine
Director, Duke Comprehensive Cancer Center

RCB/sc

Duke University Medical Center

DURHAM, NORTH CAROLINA 27710

DEPARTMENT OF SURGERY
IOX 3873

24 March 1994

TELEPHONE (919) 684-6133
FAX (919) 681-6291

To whom it may concern,

Dr. Azza Abou Ghalia has worked in my laboratory during the past 15 months, from the beginning of 1993 through March 1994. She has been under my direct supervision during this entire period and I am therefore in a good position to judge her abilities, knowledge, determination, and suitability as a scientist. Dr. Ghalia began her work on a new molecular technique to detect low levels of mutant genes amidst many copies of a wild-type gene. The purpose of these studies was to confirm and quantitate the presence of malignant cells in the bone marrow of breast and ovarian cancer patients undergoing autologous bone marrow transplantation by detecting p53 mutations. The technique employed was the ligase chain reaction (LCR), a recently developed and highly experimental method similar in concept to the polymerase chain reaction. Our laboratory had no previous experience with this technique before Azza began. She was able to develop LCR to a point where it functioned reproducibly. The assay had many inherent technical problems and through her diligence, Azza was able to overcome all of them. The final outcome of these experiments, however, was the realization that the sensitivity and specificity of the LCR was insufficient for detecting rare malignant cells. This conclusion was not made lightly. Azza attempted many permutations of the original protocol in order to overcome these barriers. Only after this arduous process did we unequivocally conclude that the technique, as currently configured, was functional but not for the original purpose. I feel confident that the LCR can now be used in my laboratory for other purposes, only as a result of Azza's efforts.

Azza did other work that was related to developing the LCR assay and in all instances, carried it out with patience, care, and diligence. We had many long discussions over experiments and experimental details. She was able to pick up protocols and techniques very quickly and understood the nuances involved. Azza was always a pleasure to work with and interacted well with everyone in the laboratory. She was an asset in my laboratory and will certainly be a greater asset in the future with her added experience gained at Duke University. She has the makings of a skilled and dedicated medical scientist and brings a rare dedication to her work. I wish Dr. Ghalia well in all her future endeavors.

Sincerely,



Jeffrey R. Marks, Ph.D.

THIS WORK IS DEDICATED TO MY SON

LIST OF FIGURES

Fig. (1): Simplified schematic representation of flow cytometry	21
Fig. (2): Cell sorting by droplet deflection	27
Fig. (3): Ligase chain reaction scheme	50
Fig (4): Flow diagram for immunofluorescence staining procedure	60
Fig. (5): Flow diagram for immunohistochemical technique	63
Fig. (6): DNA extraction from paraffin embedded breast cancer tissue	68
Fig. (7): Relation of PCR and LCR oligonucleotide primers to mutations at exon 5 (codon 175) and exon 8 (codon 238) of p53 gene.	74
Fig. (8): Flow diagram for TLC purification of the oligonucleotides	75
Fig. (9): Representative dot plots obtained with FAC star plus (A-D) cell sorter comparing the efficiency of single colour versus two colour immunofluorescence for detection of breast cancer cells.	86
Fig.(10): SKBr3 cells stained with PAP stain after FACS sorting of sample containing malignant cells only as a positive control.	89
Fig.(11): SKBr3 cells stained with PAP stain after flow cytometric cell sorting of a sample containing 10% SKBr3 breast cancer cells and 90% normal bone marrow cells.	90
Fig.(12): A single tumor cell isolated by FACS from mixture of SKBr3 breast cancer cells and normal bone marrow cells in a ratio of 1 : 100,000 and detected by cytology (PAP staining). The large size of the cell, the high nuclear / cytoplasmic ratio and	91

irregular chromatin confirm the malignant nature of this green stained cell.

- Fig.(13):** A group of cells clumped together that stained with anti-tumor antibodies and anti-CD45 in a sample containing a mixture of normal bone marrow cells and SKBr3 breast cancer cells after sorting with FACS and staining with PAP stain. 92
- Fig.(14):** Detection of breast cancer cells in human bone marrow with one-colour and two colour immunofluorescence. 95
- Fig.(15):** 12% denaturing urea polyacrylamide gel analysis of ligase chain reaction amplification product of p53 gene with mutation at codon 238 using different target concentrations 104
- Fig.(16):** Autoradiogram of 12% denaturing urea polyacrylamide gel comparing the ligation products obtained in the presence of salmon sperm and yeast DNA. 105
- Fig.(17):** Autoradiogram for 12% denaturing urea polyacrylamide gel showing the importance of using the suitable annealing temperature on doing ligation reactions. 108
- Fig.(18):** Autoradiogram of 12% denaturing urea polyacrylamide gel showing the difference of ligation signals obtained with wild and mutant plasmids DNA on using 66 & 70 °C annealing temperatures to test for p53 mutation at codon 175. 109
- Fig.(19):** Autoradiogram of 12% denaturing urea polyacrylamide gel showing the ligation products obtained with different concentrations of DNA with mutations at codon 175 of p53 gene 110
- Fig.(20):** Ethidium bromide stained 1.5% agarose gel showing polymerase chain reaction amplification product of dilution series of plasmids DNA containing p53 mutation (codon 238), using 7F, 7R exonic primers and 40 amplification cycles each with 48 C 116

annealing temperature.

- Fig.(21):** Autoradiogram for 12% denaturing urea polyacrylamide gel showing the effect of preamplification of the target DNA using polymerase chain reaction before ligase chain reaction for exon 5 of p53 gene. 117
- Fig.(22):** Autoradiogram of 12% denaturing urea polyacrylamide gel showing the ligation products obtained with 0.1-10 pg mutant DNA of p53 gene preamplified in a polymerase chain reaction . 118
- Fig.(23):** 1.5% ethidium bromide stained agarose gel showing polymerase chain reaction amplification of p53 gene present in genomic DNA extracted from { 2 cell lines, HMEC and MCF7 with no mutation at codon 175 } and paraffin embedded breast cancer tissue with p53 mutation at the same codon}. 120
- Fig.(24):** Showing migration of the 2 oligonucleotides (LN1, LN2) complementary to one strand of DNA with p53 mutation at codon 238 on thin layer chromatography plate after 5 hours. 125
- Fig.(25):** Showing thin layer chromatography plate with 4 single bands corresponding to 4 oligonucleotides complementary to both strands of target DNA with p53 mutation after its purification by TLC. 126
- Fig.(26):** Autoradiogram for 12% denaturing urea polyacrylamide gel illustrating the effect of thin layer chromatography purification of the hot oligonucleotides. 127
- Fig. (27):** Polymerase chain reaction amplification of exon 5 of 36 ng (HMEC) DNA using 5F and 5R exonic primers and VENT polymerase for 30 cycles with 65 °C annealing temperature 129
- Fig. (28):** Polymerase chain reaction amplification product of exon 5 in 36 ng genomic (HMEC) DNA using 5 F and 5 R exonic primers and VENT polymerase for 30 amplification cycles with 131

55 °C annealing temperature.

Fig. (29): Ethidium bromide stained 1.5% agarose gel showing polymerase chain reaction amplification product of exon 5 of different concentrations of genomic DNA using 5F and 5R exonic primers, Taq polymerase and 55 °C annealing temp. for 30, 40 amplification cycles for each sample. 133

Fig. (30): Autoradiogram for 10% denaturing urea polyacrylamide gel showing the effect of number of PCR cycles on the product of ligase chain reaction. 134

Fig. (31): Autoradiogram of ligase chain reaction amplification product for PCR-amplified exon 5 of p53 gene illustrating (1) the decrease of non specific ligation bands obtained on using decreasing amounts of ampligase and (2) the presence of p53 mutation in DNA extracted from paraffin embedded breast cancer tissue. 136

LIST OF TABLES

	<i>Page</i>
Table (1): Some of the biological parameters that may be measured using flow cytometry	20
Table (2): Murine monoclonal antibodies reactive with human breast cancer.	57
Table (3): Different types of DNAs amplified by polymerase chain reaction prior to ligase chain reaction	67
Table (4): Genomic DNA PCR primers	71
Table (5): LCR primers (name and sequence)	73
Table (6): Comparison of specificity and sensitivity of three different monoclonal antibody cocktails for detecting SKBr3 tumor cells mixed with normal bone marrow cells.	81
Table (7): FACS analysis of monoclonal antibody binding to SKBr3 cells after incubation for different lengths of time in the presence or absence of sodium azide	83
Table (8): Comparison of one color vs two color flow cytometric cell sorting.	94

Table (9): (A-C)	Comparison of flow cytometry/cytology with immunohistochemistry and immunofluorescence methods for the detection of breast cancer cells contaminating normal marrow cells.	97
Table (10):	Summary for the conditions used to test mutations at codon 175 and 238 of p53 gene using ligation reactions.	112
Table (11):	Different types of negative controls used in ligation reactions and showed faint bands at the same site of ligation product.	122

LIST OF ABBREVIATIONS.

ATP	: Adenosine triphosphate.
DNA	: Deoxy ribonucleic acid.
dNTP	: Deoxy nucleoside triphosphate.
FACS	: Fluorescent activated cell sorter.
FBS	: Foetal bovine serum.
FCM	: Flow cytometry.
FCS	: Flow cytometric cell sorting.
FITC	: Flourescine isothiothyanate.
HMEC	: Human mammary epithelial cell line.
LCR	: Ligase chain reaction.
MOAB	: Monoclonal antibody.
MERS	: Oligomers.
PCR	: Polymerase chain reaction.
PBS	: Phosphate buffer saline.
RNA	: Ribonucleic acid.
S phase	: Synthetic phase.
TAQ polymerase	: Thermus aquaticus polymerase.
TEA	: Tris edeta acetate.
TLC	: Thin layer chromatography.
Tm	: Melting temperature.

CONTENTS

* INTRODUCTION AND AIM OF WORK	1
* REVIEW OF LITERATURE	
Marrow micrmetastases in breast cancer	6
Flow cytometry	18
p53 oncogene	30
Polymerase chain reaction	39
Ligase chain reaction	48
* MATERIAL AND METHODS	54
* RESULTS:	
Results of flow cytometric work	79
Results of molecular biology work	99
* DISCUSSION	137
* SUMMARY AND CONCLUSIONS	154
* REFERENCES	158
* ARABIC SUMMARY.	